HBW
RNAC icon

Hazlett, Burt & Watson’s Cartesian Therapeutics RNAC Stock Holding History

Hazlett, Burt & Watson’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed – – 775
2024
Q3 		$0 Hold
12
– – ﹤0.01% 744
2024
Q2 		$0 Sell
12
-1
-8% -$24 ﹤0.01% 723
2024
Q1 		$0 Hold
13
– – ﹤0.01% 730
2023
Q4 		$0 Hold
13
– – ﹤0.01% 727
2023
Q3 		$0 Hold
13
– – ﹤0.01% 748
2023
Q2 		$0 Hold
13
– – ﹤0.01% 707
2023
Q1 		$1K Hold
13
– – ﹤0.01% 602
2022
Q4 		$0 Hold
13
– – ﹤0.01% 640
2022
Q3 		$1K Hold
13
– – ﹤0.01% 602
2022
Q2 		$0 Hold
13
– – ﹤0.01% 606
2022
Q1 		$0 Buy
+13
New +$813 ﹤0.01% 587

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hazlett, Burt & Watson's RNAC Position: Q4 2024 in Review

Hazlett, Burt & Watson sold out of Cartesian Therapeutics (RNAC) in Q4 2024, closing a stake of 12 shares.

Hazlett, Burt & Watson first reported a position in RNAC in Q1 2022 and held it in 11 quarters. The position peaked at $1K in Q1 2023. 68 funds tracked by Wall St. Rank hold RNAC as of Q4 2024.

  • Hazlett, Burt & Watson reported no remaining Cartesian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Hazlett, Burt & Watson sold 12 Cartesian Therapeutics shares in Q4 2024.
  • Hazlett, Burt & Watson first reported a position in Cartesian Therapeutics in Q1 2022 and held it in 11 quarters.
  • Hazlett, Burt & Watson's Cartesian Therapeutics position peaked at $1K in Q1 2023.
  • 68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2024.

Based on Hazlett, Burt & Watson's 13F filing for Q4 2024, filed 12 Feb 2025.